Endogenously occurring β-carboline induces parkinsonism in nonprimate animals: A possible causative protoxin in idiopathic Parkinson's disease

Journal of Neurochemistry

Volumn 70, Issue 2, 1998, Pages 727-735

  Matsubara, Kazuo ^a   Gonda, Tatsuo ^b   Sawada, Hideyuki ^c   Uezono, Takashi ^b   Kobayashi, Yuta ^b   Kawamura, Takashi ^c   Ohtaki, Ko Ichi ^a   Kimura, Kojiro ^b   Akaike, Akinori ^c  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b SHIMANE UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Animal model; Bradykinesia; Dopamine; N Methylation; Nigrostriatal degeneration; Parkinsonism; Carboline

Indexed keywords

BETA CARBOLINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE; NEUROTOXIN; PROTOXIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRADYKINESIA; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EMBRYO; EXTRAPYRAMIDAL SYMPTOM; IDIOPATHIC DISEASE; INTRAPERITONEAL DRUG ADMINISTRATION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALIA; PARKINSONIA;

EID: 0031952527     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.70020727.x     Document Type: Article

References (36)

1. Albores R., Neafsey E. J., Drucker G., Fields J. Z., and Collins M. A. (1990) Mitochondrial respiratory inhibition by N-methylated-β-carboline derivatives structurally resembling N-methyl-4-phenylpyridine. Proc. Natl. Acad. Sci. USA 87, 9368-9372.
2. Arai N., Misugi K., Goshima Y., and Misu Y. (1990) Evaluation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism. Brain Res. 515, 57-63.
3. +), the cytotoxic metabolite of the dopaminergic neurotoxin MPTP. Life Sci. 46, 379-390.
4. +, a metabolite of MPTP, by brain synaptosomes. Biochem. Biophys. Res. Commun. 128, 1228-1232.
5. + in PC12 cells: insights into potential neurotoxicants in Parkinson's disease. J. Neurochem. 62, 1503-1510.
6. Coleman T., Ellis S. W., Martin I. J., Lennard M. S., and Tucker G. T. (1996) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4 - implications for susceptibility to Parkinson's disease. J. Pharmacol. Exp. Ther. 277, 685-690.
7. Collins M. A., Neafsey E. J., Matsubara K., Cobuzzi R. J. Jr., and Rollema H. (1992) Indole-N-methylated β-carbolinium ions as potential brain-bioactivated neurotoxins. Brain Res. 570, 154-160.
8. Date I., Felten D. L., and Felten S. Y. (1990) Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. Brain Res. 519, 266-276.
9. Drucker G., Raikoff K., Neafsey E. J., and Collins M. A. (1990) Dopamine uptake inhibitory capacities of β-carboline and 3,4-dihydro-β-carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation products. Brain Res. 509, 125-133.
10. Franklin K. B. J. and Paxinos G. (1997) The Mouse Brain in Stereotoxic Coordinates. Academic Press, San Diego.
11. Fuxe K., Janson A. M., Rosen L., Finnman U. B., Tanganelli S., Morari M., Goldstein M., and Agnati L. F. (1992) Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis. Exp. Brain Res. 88, 117-130.
12. Gonda T., Akiyoshi H., and Ichihara K. (1995) Hyperplastic innervation of vasoactive intestinal peptide in human gallbladder with cholelithiasis. Histol. Histopathol. 10, 669-672.
13. Hefti F., Enz A., and Melamed E. (1985) Partial lesions of the nigrostriatal pathway in the rat. Acceleration of transmitter synthesis and release of surviving dopaminergic neurones by drugs. Neuropharmacology 24, 19-23.
14. Heikkila R. E. and Sonsalla P. K. (1992) The MPTP-treated mouse as a model of parkinsonism: how good is it? Neurochem. Int. 20 (Suppl.), 299S-303S.
15. Hu S. C., Chang F. W., Sung Y. J., Hsu W. M., and Lee E. H. (1991) Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the substantia nigra and the locus coeruleus in BALB/ c mice. J. Pharmacol. Exp. Ther. 259, 1379-1387.
16. Javitch J. A., D'Amato R. J., Strittmatter S. M., and Snyder S. H. (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA 82, 2173-2177.
17. Jenner P., Shapira A. H. V., and Marsden C. D. (1992) New insights into the cause of Parkinson's disease. Neurology 42, 2241-2250.
18. Kaakkola S. and Teravainen H. (1990) Animal models of parkinsonism. Pharmacol. Toxicol. 67, 95-100.
19. Markey S. P., Johannessen J. N., Chiueh C. C., Burns R. S., and Herkenham M. A. (1984) Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311, 464-466.
20. Matsubara K., Neafsey E. J., and Collins M. A. (1992) Novel S-adenosylmethionine-dependent indole-N-methylation of β-carbolines in brain particulate fractions. J. Neurochem. 59, 511-518.
21. Matsubara K., Collins M. A., Akane A., Ikebuchi J., Neafsey E. J., Kagawa M., and Shiono H. (1993) Potential bioactivated neurotoxicants, N-methylated β-carbolinium ions, are present in human brain. Brain Res. 610, 90-96.
22. Matsubara K., Idzu T., Kobayashi Y., Nakahara D., Maruyama W., Kobayashi S., Kimura K., and Naoi M. (1995a) N-Methyl-4-phenylpyridinium and an endogenously formed analog, N-methylated β-carbolinium, inhibit striatal tyrosine hydroxylation in freely moving rats. Neurosci. Lett. 199, 199-202.
23. + analogs, in the lumbar cerebrospinal fluid of parkinsonian patients. Neurology 45, 2240-2245.
24. + and β-carbolinium in the striatum of conscious rats. Eur. J. Pharmacol. 315, 145-151.
25. Nakahara D., Ozaki N., and Nagatsu T. (1989) A removable brain microdialysis probe unit for in vivo monitoring of neurochemical activity. Biogen. Amines 6, 559-564.
26. + cause nigrostriatal toxicity after substantia nigra injections in rat. Brain Res. 675, 279-288.
27. Nicklas W. J., Vyas I., and Heikkila R. F. (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36, 2503-2508.
28. Ogawa N., Hirose Y., Ohara S., Ono T., and Watanabe Y. (1985) A simple quantitative bradykinesia test in MPTP-treated mice. Res. Commun. Chem. Pathol. Pharmacol. 50, 435-441.
29. Sawada H., Kawamura T., Shimohama S., Akaike A., and Kimura J. (1996) Different mechanisms of glutamate-induced neuronal death between dopaminergic and non-dopaminergic neurons in rat mesencephalic culture. J. Neurosci. Res. 43, 503-510.
30. Sayre L. M., Wang F., Arora P. K., Riachi N. J., Hank S. I., and Hoppel C. L. (1991) Dopaminergic neurotoxicity in vivo and inhibition of mitochondrial respiration in vitro by possible endogenous pyridinium-like substances. J. Neurochem. 57, 2106-2115.
31. Scatton B., Javoy-Agid F., Rouquier L., Dubois B., and Agid Y. (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 275, 321-328.
32. Seniuk N. A., Tatton W. G., and Greenwood C. E. (1990) Dose-dependent destruction of the coeruleus-cortical and nigralstriatal projections by MPTP. Brain Res. 527, 7-20.
33. Sundstrom E., Stromberg I., Tsutsumi T., Olson L., and Jonsson G. (1987) Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res. 405, 26-38.
34. Tanner C. M. and Langston J. W. (1990) Do environmental toxins cause Parkinson's disease? A critical review. Neurology 40, 17-30.
35. Tipton K. F. and Singer T. P. (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61, 1191-1206.
36. Zigmond M. J. and Stricker E. M. (1989) Animal models of parkinsonism using selective neurotoxins: clinical and basic implications. Int. Rev. Neurobiol. 31, 1-79.